 LONDON, Dec. 08, 2022 GLOBE NEWSWIRE Autolus Therapeutics plc Nasdaq: AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of its previously announced underwritten public offering in the United States of 75,000,000 American Depositary Shares ADSs representing 75,000,000 ordinary shares at a public offering price of 2.00 per ... The post Autolus Announces Pricing of Public Offering appeared first on ForexTV... 